Silencing of SLFN11 or ATM did not alter PARP1 levels (Figure 4B), and PARP1 itself did not predict sensitivity to PARP inhibitors in our SCLC PDXs or cell lines. This evidence concerns the gene SLFN11 and small cell lung carcinoma.